Challenge accepted. Our country has made numerous strides in advancing patient care, and more particularly conducting efforts to ensure that lives within the national opioid crisis are saved and/or improved. One of those positive strides involves the FDA approval of abuse-deterrent formulation (ADF) opioid medications, with the aim of preventing the transition from the misuse and/or abuse of prescription opioid medications to illicit (and possibly laced) diacetylmorphine (aka, heroin). How do these formulations work? What ADF opioid medications are not only specifically approved as an ADF opioid medication, but also available on the US market? Are these ADFs really foolproof? The street chemists of our country have already accepted the challenge to be knowledgeable on all of the above and now it’s our turn as healthcare professionals to get up to speed on these risk reduction entities.